A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects

American Journal of Transplantation

Volumn 13, Issue 4, 2013, Pages 1040-1046

  Goldwater, R ^a   Keirns, J ^b   Blahunka, P ^b   First, R ^b   Sawamoto, T ^b   Zhang, W ^b   Kowalski, D ^b   Kaibara, A ^b   Holman, J ^a  

^a HARBOR HOSPITAL   (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

anti CD40; ASKP1240; pharmacodynamics; pharmacokinetics; randomized

Indexed keywords

ASKP1240; CD40 LIGAND MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACKACHE; CONTACT DERMATITIS; CONTROLLED STUDY; COUGHING; CYTOKINE RELEASE SYNDROME; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; FLATULENCE; HEADACHE; HEMATOMA; HUMAN; IMMUNOGENICITY; INCIDENCE; INJECTION SITE PAIN; MALE; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SEROCONVERSION; SINGLE DRUG DOSE; THROMBOEMBOLISM; TIME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; AREA UNDER CURVE; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 84875691131     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12082     Document Type: Article

References (17)

1. Rothstein DM, Sayegh MH,. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev 2003; 196: 85-108. (Pubitemid 37468106)
2. Gudmundsdottir H, Turka LA,. T cell costimulatory blockade: New therapies for transplant rejection. J Am Soc Nephrol 1999; 10: 1356-1365. (Pubitemid 29247003)
3. Aoyagi T, Yamashita K, Suzuki T, et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: Induction and maintenance therapy. Am J Transplant 2009; 9: 1732-1741.
4. Miura T, Okimura K, Takahash iN, Kataoka S,. Pharmacological and toxicological studies of a fully human antibody (4D11) against human CD40 in human samples in vitro and nonhuman primates in vivo. Am J Transplant 2005; 5 (11 Suppl): 420.
5. Imai A, Suzuki T, Sugitani A, et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation 2007; 84: 1020-1028. (Pubitemid 350287383)
6. Kernstock R,. Bioanalytical Validation Report IC-2009-001. Validation of an Analytical Method for the Determination of ASKP1240 in Human Serum using Electrochemiluminescence. February 26, 2010. Skokie, IL, USA: Astellas Pharma Global Development, Inc.; 2010.
7. Kernstock R,. Bioanalytical Validation Report IC-2009-002. Validation of an analytical method for the screening, confirmation, and titer for the presence of anti-ASKP1240 antibodies in human serum using electrochemiluminescence detection. February 26, 2010. Skokie, IL, USA: Astellas Pharma Global Development, Inc.; 2010.
8. Kirk AD, Knechtle SJ, Vincenti FG, Nadeau KC,. Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation [abstract] Am J Transplant 2001; 1 (Suppl 1): 191.
9. Boumpas DT, Furie R, Manzi S, Illei GG, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheumatism 2003; 48: 719-727. (Pubitemid 36302008)
10. Pree I, Wekerle T,. New approaches to prevent transplant rejection: Co-stimulation blockers anti-CD40L and CTLA41g. Drug Discov Today 2006; 3: 41-47.
11. Sidiropoulos PI, Boumpas DT,. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004; 13: 391-397. (Pubitemid 38788502)
12. Tabrizi MA, Tseng CL, Roskos LK,. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discoveries Therapeutics 2006; 11: 81-88. (Pubitemid 43227856)
13. Bensinger W, Maziarz RT, Jagannath S, et al. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. British Journal of Haematology 2012; 159: 58-66.
14. Advani R, Forero-Torres A, Furman RR, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4371-4377.
15. Hussein M, Berenson JR, Niesvizky R, et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 2010; 95: 845-848.
16. Kasran A, Boon L, Wortel CH, et al. Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther 2005; 22: 111-122. (Pubitemid 41039699)
17. Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007; 25: 876-883. (Pubitemid 350002889)